Eupraxia Pharmac SEC Filings

Eupraxia Pharmaceuticals Inc. reported a larger net loss for the three months ended March 31, 2026 as it accelerated spending on its EP-104 pipeline. Net loss was $12.7 million compared with $6.8 million a year earlier, driven mainly by higher research and development and corporate costs.

Research and development expenses more than doubled to $11.2 million, reflecting expanded clinical activity in eosinophilic esophagitis and related programs, while general and administrative expenses rose to $4.8 million. To support this growth, Eupraxia completed a February 2026 equity financing, raising roughly $63.2 million gross through common shares and pre-funded warrants.

Despite the higher loss, the company ended the quarter with a substantial cash position: cash and cash equivalents of $58.5 million and short-term investments of $80.4 million, backing ongoing Phase 1b/2 work in EP-104GI and strategic options for EP-104IAR. Management continues to emphasize the need for future financings or partnerships to fund later-stage trials and potential commercialization.

Eupraxia Pharmaceuticals reported new tissue-based results from the Phase 1b/2a RESOLVE trial of EP-104GI in eosinophilic esophagitis (EoE). Using the EoE Histology Scoring System (EoEHSS), inflammation sub scores improved in all reported cohorts at 12 weeks (n=31) and 36 weeks (n=27).

Tissue architecture and fibrosis sub scores also improved across most cohorts. At the highest dose cohort, grade and stage improvements in inflammatory scores exceeded 90%, and architectural/fibrotic scores improved by more than 83% at both 12 and 36 weeks. These findings align with earlier symptom and endoscopic (EREFS) improvements.

The open-label dose-escalation portion of RESOLVE follows patients up to 24 or 52 weeks, depending on cohort. A randomized, placebo-controlled Phase 2b part of RESOLVE is now recruiting 120 mg and 160 mg doses of EP-104GI, with top-line data expected in Q4 2026.

Eupraxia Pharmaceuticals reported new endoscopic EREFS data from the Phase 1b/2a part of its RESOLVE trial of EP-104GI in eosinophilic esophagitis (EoE). The company presented the results at Digestive Disease Week in Chicago.

Among participants with baseline EREFS scores above 2, the share of responders (scores ≤2) at week 12 rose with more esophageal injections. In 7 patients who received 20 injections, mean EREFS fell 65% (3.6 points), with near-complete improvement in the highest-dose cohorts. These findings support using 20 injections in the ongoing placebo-controlled Phase 2b trial, which is enrolling 120mg (20x6mg) and 160mg (20x8mg) doses with top-line data expected in Q4 2026.

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, has appointed Dr. Jeymi Tambiah as Chief Medical Officer, succeeding retiring CMO Dr. Mark Kowalski, who will remain as a senior consultant during the transition. Dr. Tambiah brings over 18 years of biopharmaceutical clinical development, medical and regulatory strategy, and commercialization experience, particularly in immunology and late-stage programs.

The company is advancing EP-104GI for Eosinophilic Esophagitis in its RESOLVE Phase 1b/2 trial and previously completed the SPRINGBOARD Phase 2b trial of EP-104IAR for knee osteoarthritis, which met its primary endpoint and most secondary endpoints. Eupraxia’s Diffusphere™ technology is designed for targeted, extended-release, locally delivered therapies in areas of high unmet medical need.

Eupraxia Pharmaceuticals Inc. is highlighting new clinical data for its lead candidate EP-104GI in eosinophilic esophagitis at the Digestive Disease Week 2026 conference. The company will present one oral and three poster abstracts from the ongoing Phase 1b/2 RESOLVE trial, including 36‑week histology, endoscopy and symptom durability results.

Eupraxia will also host a virtual investor event on May 4, 2026, featuring key opinion leaders discussing recurrent esophageal strictures and the potential of EP-104GI, a long-acting submucosal corticosteroid injection. The filing also notes earlier success of EP-104IAR, which met its primary endpoint in a Phase 2b knee osteoarthritis trial.

Eupraxia Pharmaceuticals reported new 36‑week results from the highest dose cohort (Cohort 9, n=3) of its Phase 1b/2a RESOLVE trial testing EP‑104GI in eosinophilic esophagitis. Patients showed robust, sustained improvements in both tissue health and swallowing symptoms compared with their own baselines.

EoEHSS Stage and Grade scores in Cohort 9 improved by 0.59 and 0.53 at week 36, corresponding to 90% and 88% reductions, with benefits seen in both inflammatory and structural components. Peak Eosinophil Count fell 72% from baseline, the largest reduction among all dose levels.

Symptoms, measured by the Straumann Dysphagia Index, improved by an average of 3 points at week 36, meeting the trial’s definition of clinical remission; 2 of 3 patients maintained remission from weeks 8 through 36. Across 31 patients and more than 230 patient‑months of follow‑up, EP‑104GI has been generally well tolerated with no drug‑related serious adverse events, no oropharyngeal candidiasis, and no adrenal or glucose derangements. A placebo‑controlled Phase 2b portion of RESOLVE using high doses is ongoing, with top‑line data expected in Q4 2026.

Eupraxia Pharmaceuticals Inc. filed a Form 6-K highlighting upcoming investor conference participation and summarizing its drug-development focus. The company’s management will hold 1x1 meetings at the Raymond James Biotech Innovation Symposium on April 14, 2026 in New York.

Eupraxia will also present and host 1x1 meetings at the Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 21-22, 2026, with a webcasted presentation on April 21 from 11:00AM to 11:30AM. The company is a clinical-stage biotechnology firm developing locally delivered, extended-release therapies using its proprietary Diffusphere™ micro-sphere technology.

Eupraxia Pharmaceuticals Inc. has scheduled its Annual General Meeting of security holders for June 18, 2026. Holders of common shares on the record date of May 8, 2026 are entitled to receive notice of the meeting and to vote. The meeting is described as an Annual General Meeting, with common shares being the sole class eligible for notice and voting rights. Proxy-related and delivery details for beneficial owners are addressed through TSX Trust Company.

Eupraxia Pharmaceuticals reported encouraging six-month symptom data from the highest dose cohort in the Phase 1b/2a RESOLVE trial of EP-104GI for eosinophilic esophagitis. In the top dose group (n=3), patients showed a mean 4-point reduction in Straumann Dysphagia Index scores, where a 3-point drop is considered clinical remission.

Across dose cohorts 4-9, 59% of patients achieved clinical remission at 12 weeks, 76% of evaluable patients maintained remission at 24 weeks, and 67% at 52 weeks. A new 6 mg/site cohort using larger catheters (Cohort 8b) showed substantially better histologic, symptom, and eosinophil reductions than an earlier 6 mg/site cohort, supporting improved drug delivery.

EP-104GI has been well tolerated, with 31 patients and over 220 patient-months of follow-up, no serious adverse events, and no oropharyngeal candidiasis or adrenal or glucose issues reported. The randomized, placebo-controlled Phase 2b portion of RESOLVE, testing 120 mg and 160 mg doses, is ongoing, with top-line data expected in Q3 2026.